Biocon will pay $5.5 billion to combine its biologics division | India News
Kiran Mazumdar-Shaw said the combined entity would position Biocon among the few global players with scale in both generics and biologics NEW DELHI: Biocon will fully integrate its biosimilars arm, Biocon Biologics, into the parent in a deal valuing the unit at $5.5 billion. The move is aimed at creating a unified biopharma powerhouse, and…
